Denosumab News and Research

RSS
Denosumab is a fully human monoclonal antibody that targets RANK Ligand and is being investigated for its potential to prevent and treat a broad range of bone disease conditions including osteoporosis, bone metastases and their consequences, cancer treatment-induced bone loss due to hormone ablative therapy, multiple myeloma and bone erosions in rheumatoid arthritis. Denosumab is the first late-stage investigational therapy that specifically inhibits RANK Ligand, an essential mediator of the cells that break down bone.
FDA approves new osteoporosis drug for postmenopausal women with high fracture risk

FDA approves new osteoporosis drug for postmenopausal women with high fracture risk

Benefits of osteoporosis treatment in postmenopausal women outweigh the perceived risks

Benefits of osteoporosis treatment in postmenopausal women outweigh the perceived risks

New treatment option appears promising for patients with glucocorticoid-induced osteoporosis

New treatment option appears promising for patients with glucocorticoid-induced osteoporosis

Drug holiday from bisphosphonates for more than two years linked to higher hip fracture risk in women

Drug holiday from bisphosphonates for more than two years linked to higher hip fracture risk in women

ACR’s updated guideline provides recommendations on treatment of glucocorticoid-induced osteoporosis

ACR’s updated guideline provides recommendations on treatment of glucocorticoid-induced osteoporosis

Thyroid cancer patients with bone metastases have worse survival, study finds

Thyroid cancer patients with bone metastases have worse survival, study finds

Amgen, UCB present romosozumab Phase 2 results at ENDO 2017

Amgen, UCB present romosozumab Phase 2 results at ENDO 2017

New study provides reassuring information about safety of osteoporosis drug

New study provides reassuring information about safety of osteoporosis drug

New guidelines recommend evaluation of osteoporosis risk for all postmenopausal women

New guidelines recommend evaluation of osteoporosis risk for all postmenopausal women

Denosumab drug that inhibits RANKL gene can prevent genetic breast cancer

Denosumab drug that inhibits RANKL gene can prevent genetic breast cancer

Romosozumab for postmenopausal women with osteoporosis meets co-primary endpoints in Phase 3 study

Romosozumab for postmenopausal women with osteoporosis meets co-primary endpoints in Phase 3 study

Monoclonal antibody reduces relapse rate by 18% in postmenopausal, HR-positive breast cancer patients

Monoclonal antibody reduces relapse rate by 18% in postmenopausal, HR-positive breast cancer patients

Adjuvant denosumab improves disease-free survival for postmenopausal women with early-stage, HR+ breast cancer

Adjuvant denosumab improves disease-free survival for postmenopausal women with early-stage, HR+ breast cancer

Scientists report that mouse with weak bones appears to have strong metabolism

Scientists report that mouse with weak bones appears to have strong metabolism

New guidance to prevent bisphosphonate-related atypical femoral fractures

New guidance to prevent bisphosphonate-related atypical femoral fractures

Amgen's XGEVA (denosumab) receives FDA approval for treatment of hypercalcemia of malignancy

Amgen's XGEVA (denosumab) receives FDA approval for treatment of hypercalcemia of malignancy

Denosumab increases bone density for postmenopausal women with osteoporosis

Denosumab increases bone density for postmenopausal women with osteoporosis

Study compares efficacy and side effects of popular osteoporosis drugs

Study compares efficacy and side effects of popular osteoporosis drugs

Advanced prostate cancer therapies: an interview with Dr. Nancy Dawson, Lombardi Comprehensive Cancer Center

Advanced prostate cancer therapies: an interview with Dr. Nancy Dawson, Lombardi Comprehensive Cancer Center

IOF outlines guidelines to help prevent osteoporosis and fractures in cancer patients

IOF outlines guidelines to help prevent osteoporosis and fractures in cancer patients